uploads///Chart

A Look at Eli Lilly’s New Products in Q2 2018

By

Updated

New products portfolio

Eli Lilly and Company’s (LLY) new products portfolio includes new products that have been launched since 2014. The portfolio includes drugs such as Basaglar, Cyramza, Jardiance, Lartruvo, Olumiant, Taltz, Trulicity, and the latest product, Verzenio.

The chart above compares the revenues for LLY’s new products since the first quarter of 2017. The performances of Cyramza and Lartruvo were discussed in the previous articles.

Article continues below advertisement

Basaglar

Basaglar is an insulin glargine injection. Basaglar reported a 133% YoY rise in revenue to ~$201.8 million in the second quarter compared to ~$86.6 million in the second quarter of 2017 due to an increase in US sales to ~$156.5 million and nearly flat international sales at ~$45.3 million in the quarter.

Jardiance

Jardiance is part of Boehringer Ingelheim and Eli Lilly’s diabetes alliance. Jardiance reported a 43% rise in YoY revenue to ~$147.2 million in the second quarter compared to $103.2 million in the second quarter of 2017. Its US sales rose 28%, while its international sales rose 70% during the quarter.

Article continues below advertisement

Taltz

Taltz reported a 59% rise in YoY revenue to $220.1 million in the second quarter compared to $138.7 million in the second quarter of 2017. Its US sales were $174 million, while its international sales were $46 million in the quarter.

Trulicity

Trulicity reported a 62% rise in YoY revenue to $779.8 million during the second quarter compared to $480.2 million in the second quarter of 2017. Its US sales rose ~61%, while its international sales rose ~69% during the quarter.

Verzenio

Verzenio is a new oncology drug for the treatment of HR+ and HER2- advanced breast cancer or metastatic breast cancer. The drug was launched in US markets in the fourth quarter of 2017, and it reported revenue of $57.7 million in the second quarter.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 8.8% in Eli Lilly, 7.8% in Abbott Laboratories (ABT), 8.3% in Merck & Co. (MRK), and 8.2% in Pfizer (PFE).

Advertisement

More From Market Realist